Lecanemab: Alzheimer's, press releases and relative risk
Play • 8 min
Lecanemab is the shiny new medicine for Alzheimer's that's been in the press - a 27% decrease in progression sounds great, plus it's a 'mab, so it must be cool. But how might it work, what do we actually know from the press release, and what do we need to have a closer look at?
More episodes
Clear search
Close search
Google apps
Main menu